1-7 of 7
Marco DiBonaventura
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Free
Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte
Journal: Blood
Blood (2024) 144 (Supplement 1): 1933.
https://doi.org/10.1182/blood-2024-203723
Published: 2024
Journal Articles

The Impact of Multiple Myeloma on Care Partner Well-Being, Work Productivity, and Resource Use in the United States and Western Europe

Free
Kathy Annunziata, Nikoletta Sternbach, Hitomi Tanaka, Marco DiBonaventura, Joseph C. Cappelleri, Jack Watkins, David Hughes, Aster Meche, Chai Hyun Kim, C. Todd Kennedy, Hans Scheurer, Thomas W. LeBlanc
Journal: Blood
Blood (2024) 144 (Supplement 1): 3762.
https://doi.org/10.1182/blood-2024-201802
Published: 2024
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study - Interim Results

Free
Charis Charalampous, Shaji Kumar, Ricardo D. Parrondo, Saurabh Chhabra, Madhu Nagaraj, Mei Sheng Duh, Priyanka J. Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Rickard Sandin, Joseph C. Cappelleri, David Hughes, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2024) 144 (Supplement 1): 3770.
https://doi.org/10.1182/blood-2024-204005
Published: 2024
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival, Duration of Response, and Overall Survival from MagnetisMM-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Free
Luciano J. Costa, Thomas W. LeBlanc, Hans Tesch, Pieter Sonneveld, Sarasa M.A. Johnson, Francis Vekeman, Patrick Hlavacek, Aster Meche, Paul Cislo, David Hughes, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2024) 144 (Supplement 1): 2401.
https://doi.org/10.1182/blood-2024-203920
Published: 2024
Journal Articles

Patient-Reported Outcomes Among Patients with Triple-Class Refractory Multiple Myeloma in Real-World Clinical Practice: A Prospective, Multi-Site Observational Study

Free
Charalampos Charalampous, Shaji Kunnathu Kumar, Ricardo Parrondo, Saurabh Chhabra, Mei Sheng Duh, Priyanka Bobbili, Aolin Wang, Jingyi Chen, Manasi Mohan, Patrick Hlavacek, Jinma Ren, Alex Schepart, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6727.
https://doi.org/10.1182/blood-2023-180984
Published: 2023
Journal Articles

An Indirect Comparison of Elranatamab's Progression-Free Survival and Overall Survival from Magnetismm-3 Versus Real-World External Control Arms in Triple-Class Refractory Multiple Myeloma

Free
Luciano Costa, Thomas W LeBlanc, Hans Tesch, Pieter Sonneveld, Ryan Kyle, Liliya Sinyavskaya, Patrick Hlavacek, Aster Meche, Jinma Ren, Alex Schepart, Didem Aydin, Guido Nador, Marco DiBonaventura
Journal: Blood
Blood (2023) 142 (Supplement 1): 6716.
https://doi.org/10.1182/blood-2023-180848
Published: 2023
Journal Articles

Treatment Patterns and Hydroxyurea Response Among Patients with Polycythemia Vera

Free
Shreekant Parasuraman, PhD, Marco DiBonaventura, PhD, Kelly Reith, MS,MBA, Kristen Concialdi, BA
Journal: Blood
Blood (2014) 124 (21): 1852.
https://doi.org/10.1182/blood.V124.21.1852.1852
Published: 2014